IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Foundations Investment Advisors LLC

Key Points

• Foundations Investment Advisors LLC reduced its stake in IQVIA Holdings Inc. by 33.6%, selling 1,938 shares, leaving it with 3,837 shares valued at approximately $676,000.
• Insider trading activity included sales by Eric Sherbet and Keriann Cherofsky, reducing their ownership by 17.59% and 15.87%, respectively.
• IQVIA reported quarterly earnings of $2.81 per share, exceeding analyst expectations, with revenues of $4.02 billion, marking a 5.3% year-over-year increase.

Foundations Investment Advisors LLC decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 33.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,837 shares of the medical research company's stock after selling 1,938 shares during the quarter. Foundations Investment Advisors LLC's holdings in IQVIA were worth $676,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. Nemes Rush Group LLC raised its stake in shares of IQVIA by 15.0% during the 1st quarter. Nemes Rush Group LLC now owns 621 shares of the medical research company's stock worth $109,000 after buying an additional 81 shares in the last quarter. LPL Financial LLC raised its position in IQVIA by 5.8% in the first quarter. LPL Financial LLC now owns 102,121 shares of the medical research company's stock worth $18,004,000 after acquiring an additional 5,615 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of IQVIA by 8.7% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 91,955 shares of the medical research company's stock worth $16,212,000 after purchasing an additional 7,382 shares in the last quarter. Empirical Finance LLC grew its stake in shares of IQVIA by 2.4% during the 1st quarter. Empirical Finance LLC now owns 6,374 shares of the medical research company's stock worth $1,124,000 after purchasing an additional 152 shares during the period. Finally, Motco boosted its holdings in IQVIA by 7.6% during the first quarter. Motco now owns 41,476 shares of the medical research company's stock worth $7,312,000 after buying an additional 2,915 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IQV shares. Redburn Partners set a $188.00 price target on shares of IQVIA in a research report on Friday, May 23rd. William Blair reissued an "outperform" rating on shares of IQVIA in a report on Wednesday, July 23rd. Truist Financial lifted their price target on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a report on Thursday, May 22nd. Finally, Mizuho raised their price objective on shares of IQVIA from $190.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday, July 25th. Seven analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.

IQVIA Stock Up 0.2%

NYSE IQV traded up $0.42 during trading hours on Monday, hitting $182.87. The company had a trading volume of 649,047 shares, compared to its average volume of 2,025,203. The firm's 50 day moving average is $162.11 and its 200 day moving average is $169.70. The company has a market capitalization of $31.09 billion, a price-to-earnings ratio of 26.48, a P/E/G ratio of 2.00 and a beta of 1.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The firm had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same period in the previous year, the company posted $2.64 EPS. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of IQVIA stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.